Menu
Annual · values202520242023202220212020201920182017201620152014
Gross Margin
Operating Margin
EBITDA Margin
Net Margin28.23%26.86%27.43%26.16%26.20%24.54%23.96%24.52%16.28%16.80%7.11%12.18%
Current Ratio3.031.753.362.373.863.052.633.603.853.032.153.19
Quick Ratio1.941.082.001.632.792.301.852.462.551.691.332.00
Debt / Equity2.711.381.321.791.451.912.382.952.772.984.102.72
ROE80.25%52.12%46.96%48.01%44.83%43.41%55.39%65.35%48.38%54.77%31.07%43.61%
ROA17.28%17.46%16.41%14.16%14.65%12.04%12.99%13.25%10.06%10.73%4.28%8.85%
Asset Turnover0.610.650.600.540.560.490.540.540.620.640.600.73
Book Value / Share7.5110.4910.809.369.537.885.624.493.623.012.172.66

Zoetis Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions. Its products serve both companion animals, such as dogs, cats, and horses, and livestock, including cattle, swine, poultry, fish, and sheep. Zoetis offers a broad portfolio spanning parasiticides, vaccines, dermatology treatments, anti-infectives, pain and sedation therapies, and nutritional and other non-pharmaceutical products, supported by point-of-care diagnostic tools, laboratory services, and monitoring technologies. The company markets its solutions primarily to veterinarians, livestock producers, and pet owners, playing a key role in supporting animal health, food production efficiency, and pet care standards worldwide. Zoetis Inc. operates across the United States and international markets and is headquartered in Parsippany, New Jersey.